GE HealthCare Technologies is under fresh valuation scrutiny following a new research collaboration with Mayo Clinic on the MI-BET theranostics trial for advanced prostate cancer. The stock has fallen 13.66% over the past 90 days to a recent price of US$63.20, with a one-year total shareholder return decline of 16.09%, amid slower reported order growth and sector concerns after HCA Healthcare's update on surgery volumes. The most followed narrative points to a fair value of US$79.72, implying the stock is 20.7% undervalued, anchored in long-term earnings and margin assumptions driven by a pipeline of products including Radiopharmaceuticals, Total Body PET, and Photon Counting CT. However, the company still faces tariff and China regulatory risks, and any stumble in new product execution could challenge the undervaluation story.
GE HealthCare Technologies Inc.New research collaboration with Mayo Clinic on MI-BET theranostics trial for advanced prostate cancer.
HCA Healthcare, Inc.HCA Healthcare's update on surgery volumes contributed to sector concerns, affecting GE HealthCare's order growth.